Report Publication Announcement • Dec 23, 2025
Report Publication Announcement
Open in ViewerOpens in native device viewer
Xlife Sciences AG / Key word(s): Miscellaneous
Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence
23.12.2025 / 07:00 CET/CEST
Zurich, 23 rd of December 2025: Xlife Sciences AG (SIX: XLS) today announced that its Board of Directors has resolved to move from the SIX Sparks segment to the main segment of the SIX Swiss Exchange. This step underscores the company’s strategic development and offers significant advantages for our investors: increased visibility, improved liquidity, and stronger recognition in the capital markets. Following a preliminary legal review, Xlife Sciences meets all requirements and will promptly submit the corresponding application to SIX.
In addition, Xlife Sciences is investing in market-making and research activities to further enhance the visibility and tradability of its shares. The segment change is planned for the first quarter of 2026.
Oliver R. Baumann, CEO of Xlife Sciences AG, stated: « Transitioning to the main segment of SIX is the next logical step for Xlife Sciences: it increases visibility, improves the liquidity of our shares, and provides additional access to institutional investors. In parallel, we are intensifying efforts in market-making and research coverage to further enhance the attractiveness for existing and new shareholders. »
Financial calendar
| Annual Report 2025 | 28 April 2026 |
| Annual Shareholders Meeting 2026 | 26 June 2026 |
| Half-Year Report 2026 | 24 September 2026 |
Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, [email protected]
Xlife Sciences AG,
Talacker 35,
8001 Zurich,
Switzerland,
Phone +41 44 385 84 60
[email protected] , www.xlifesciences.ch ,
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange
About Xlife Sciences AG (SIX:XLS)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch
Disclaimer
Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.
End of Media Release
View original content: EQS News
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2250498 |
| End of News | EQS News Service |
2250498 23.12.2025 CET/CEST
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.